Tiangu Yang1, Wei Qin2, Xiaowei Sun3, Yanhua Wang1, Jin Wu2, Zixiang Li1, Fuhua Ji2, Liang Zhang4, Wei Liu5. 1. Department of Interventional Therapy, The Affiliated Hospital of Qingdao University, Qingdao, China. 2. Department of Interventional Therapy, Rizhao Central Hospital, Qingdao, China. 3. Department of Radiology, Qingdao Women and Children's Hospital, Qingdao, China. 4. Department of Abdominal Ultrasound, The affiliated Hospital of Qingdao University, Qingdao, China. 5. Qingdao Center for Disease Control and Pervention, Qingdao, China.
Abstract
PURPOSE: To evaluate the efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE) using 100-300 μm versus 300-500 μm CalliSpheres microspheres (CSMs) for treating multiple hepatocellular carcinoma (HCC) with the largest nodule measuring between 5 and 10 cm. METHODS: Eighty-one advanced-stage HCC patients treated by DEB-TACE between January 2017 and March 2020 were retrospectively analyzed. There were 48 patients in the 100-300 μm group and 33 patients in the 300-500 μm group. Treatment response, liver function tests, and complications were compared between the two groups. RESULTS: At 6 months, the response rates in the 100-300 μm group were higher than those in the 300-500 μm group (P < 0.05). Disease control rates in the 100-300 μm group were higher than those in the 300-500 μm group at 1, 3, and 6 months (P < 0.05). Progression-free survival (PFS) and overall survival (OS) were longer in the 100-300 μm group (P < 0.05). Visual analog score points were higher in the 300-500 μm group (P < 0.05). There were no significant differences in complications between the two groups. CONCLUSION: The use of small-diameter CSMs in multiple HCC with the largest nodule size of 5-10 cm provides better treatment response and longer PFS and OS for treating advanced-stage HCC.
PURPOSE: To evaluate the efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE) using 100-300 μm versus 300-500 μm CalliSpheres microspheres (CSMs) for treating multiple hepatocellular carcinoma (HCC) with the largest nodule measuring between 5 and 10 cm. METHODS: Eighty-one advanced-stage HCC patients treated by DEB-TACE between January 2017 and March 2020 were retrospectively analyzed. There were 48 patients in the 100-300 μm group and 33 patients in the 300-500 μm group. Treatment response, liver function tests, and complications were compared between the two groups. RESULTS: At 6 months, the response rates in the 100-300 μm group were higher than those in the 300-500 μm group (P < 0.05). Disease control rates in the 100-300 μm group were higher than those in the 300-500 μm group at 1, 3, and 6 months (P < 0.05). Progression-free survival (PFS) and overall survival (OS) were longer in the 100-300 μm group (P < 0.05). Visual analog score points were higher in the 300-500 μm group (P < 0.05). There were no significant differences in complications between the two groups. CONCLUSION: The use of small-diameter CSMs in multiple HCC with the largest nodule size of 5-10 cm provides better treatment response and longer PFS and OS for treating advanced-stage HCC.